Emtora Biosciences is a biopharmaceutical company which holds the license to eRapa, a targeted formulation of rapamycin investigated to prevent cancer and other age-related medical conditions. In preclinical studies it has demonstrated that eRapa can prevent the formation of polyps in a mouse model for FAP, thus preventing the progression to colon cancer. The spheres for potential use of eRapa include oncology, immunology, neurology, and trauma.